232 related articles for article (PubMed ID: 34241600)
1. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.
Koide H; Yamauchi I; Hoshino Y; Yasuno G; Okamoto T; Akashi S; Saito K; Oku N; Asai T
Biomater Sci; 2021 Aug; 9(16):5588-5598. PubMed ID: 34241600
[TBL] [Abstract][Full Text] [Related]
2. Rational designing of an antidote nanoparticle decorated with abiotic polymer ligands for capturing and neutralizing target toxins.
Koide H; Tsuchida H; Nakamoto M; Okishima A; Ariizumi S; Kiyokawa C; Asai T; Hoshino Y; Oku N
J Control Release; 2017 Dec; 268():335-342. PubMed ID: 29061513
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of target toxin neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles.
Koide H; Suzuki H; Ochiai H; Egami H; Hamashima Y; Oku N; Asai T
Biochem Biophys Res Commun; 2021 May; 555():32-39. PubMed ID: 33812056
[TBL] [Abstract][Full Text] [Related]
4. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles containing labile PEG-lipids transfect primary human skin cells more efficiently in the presence of apoE.
Gregersen CH; Mearraoui R; Søgaard PP; Clergeaud G; Petersson K; Urquhart AJ; Simonsen JB
Eur J Pharm Biopharm; 2024 Apr; 197():114219. PubMed ID: 38368913
[TBL] [Abstract][Full Text] [Related]
8. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
9. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration.
Kurimoto S; Yoshinaga N; Igarashi K; Matsumoto Y; Cabral H; Uchida S
Molecules; 2019 Apr; 24(7):. PubMed ID: 30987102
[TBL] [Abstract][Full Text] [Related]
10. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
11. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
12. Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol.
Rafique A; Etzerodt A; Graversen JH; Moestrup SK; Dagnæs-Hansen F; Møller HJ
Int J Nanomedicine; 2019; 14():2829-2846. PubMed ID: 31114197
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of macromolecular structure evolution in self-assembled lipid nanoparticles for siRNA delivery.
Gindy ME; DiFelice K; Kumar V; Prud'homme RK; Celano R; Haas RM; Smith JS; Boardman D
Langmuir; 2014 Apr; 30(16):4613-22. PubMed ID: 24684657
[TBL] [Abstract][Full Text] [Related]
14. siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.
Sakurai Y; Yoshikawa K; Arai K; Kazaoka A; Aoki S; Ito K; Nakai Y; Tange K; Furihata T; Tanaka H; Akita H
J Control Release; 2023 Jan; 353():125-133. PubMed ID: 36414194
[TBL] [Abstract][Full Text] [Related]
15. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.
Cheng X; Lee RJ
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):129-137. PubMed ID: 26900977
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
17. CHARMM-GUI Membrane Builder for Lipid Nanoparticles with Ionizable Cationic Lipids and PEGylated Lipids.
Park S; Choi YK; Kim S; Lee J; Im W
J Chem Inf Model; 2021 Oct; 61(10):5192-5202. PubMed ID: 34546048
[TBL] [Abstract][Full Text] [Related]
18. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
19. Molecular-Level Structural Analysis of siRNA-Loaded Lipid Nanoparticles by
Ueda K; Sakagawa Y; Saito T; Fujimoto T; Nakamura M; Sakuma F; Kaneko S; Tokumoto T; Nishimura K; Takeda J; Arai Y; Yamamoto K; Ikeda Y; Higashi K; Moribe K
Mol Pharm; 2023 Sep; 20(9):4729-4742. PubMed ID: 37606988
[No Abstract] [Full Text] [Related]
20. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]